Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OTC | P00480 | 1/20 | 0.51 |
| ▸ | NOD1 | Q9Y239 | 2/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | DDAH1 | O94760 | 4/20 | 0.42 |
| ▸ | GSR | P00390 | 1/20 | 0.41 |
| ▸ | NOS2 | P35228 | 6/20 | 0.41 |
| ▸ | NOS1 | P29475 | 5/20 | 0.41 |
| ▸ | NOS3 | P29474 | 3/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.41 |
| ▸ | APEX1 | P27695 | 1/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15483719 | 0.93 | OTC (0.50) | OTCNOD1TDP1DDAH1GSR | |
| SCHEMBL15618211 | 0.92 | OTC (0.49) | OTCNOD1TDP1DDAH1GSR | |
| SCHEMBL16447237 | 0.87 | NOD1 (0.49) | OTCNOD1TDP1DDAH1GSR | |
| SCHEMBL13445977 | 0.87 | OTC (0.52) | OTCNOD1DDAH1GSRNOS2 | |
| SCHEMBL13464207 | 0.87 | OTC (0.52) | OTCNOD1DDAH1GSRNOS2 | |
| SCHEMBL22691090 | 0.87 | OTC (0.52) | OTCNOD1DDAH1GSRNOS2 | |
| SCHEMBL16446596 | 0.84 | OTC (0.46) | OTCDDAH1GSRNOS2NOS1 | |
| SCHEMBL20178595 | 0.84 | OTC (0.46) | OTCDDAH1GSRNOS2NOS1 | |
| SCHEMBL24610028 | 0.84 | OTC (0.44) | OTCNOD1DDAH1GSRNOS2 | |
| SCHEMBL15469244 | 0.84 | OTC (0.44) | OTCNOD1DDAH1GSRNOS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105026574-B | Cell lines | 米迪缪尼有限公司 | 2019-08-30 | — | — | CN | disclosed |
| US-10253345-B2 | Cell lines | MEDIMMUNE LIMITED (GB) | 2019-04-09 | — | — | US | disclosed |
| US-10253345-B2 | Cell lines | MEDIMMUNE LIMITED (GB) | 2019-04-09 | — | — | US | disclosed |
| EP-2898085-B1 | CELL LINES | MEDIMMUNE LTD (GB) | 2019-01-23 | — | — | EP | disclosed |
| EP-2898085-B1 | CELL LINES | MEDIMMUNE LTD (GB) | 2019-01-23 | — | — | EP | disclosed |
| US-20170306381-A1 | CELL LINES | ALLOZYNE, INC. | 2017-10-26 | — | — | US | disclosed |
| US-20170306381-A1 | CELL LINES | ALLOZYNE, INC. | 2017-10-26 | — | — | US | disclosed |
| US-20170306380-A1 | AMINO ACID DERIVATIVES | MEDIMMUNE LIMITED (GB) | 2017-10-26 | — | — | US | disclosed |
| CN-104812734-B | Amino acid derivatives | 米迪缪尼有限公司 | 2017-08-22 | — | — | CN | disclosed |
| US-9732367-B2 | Cell lines | MEDIMMUNE LIMITED (GB) | 2017-08-15 | — | — | US | disclosed |
| US-20150259721-A1 | CELL LINES | ALLOZYNE, INC. | 2015-09-17 | — | — | US | disclosed |
| US-20150259721-A1 | CELL LINES | ALLOZYNE, INC. | 2015-09-17 | — | — | US | disclosed |
| US-20150251994-A1 | AMINO ACID DERIVATIVES | ALLOZYNE, INC. | 2015-09-10 | — | — | US | disclosed |
| US-20150251994-A1 | AMINO ACID DERIVATIVES | ALLOZYNE, INC. | 2015-09-10 | — | — | US | disclosed |
| EP-2897935-A1 | AMINO ACID DERIVATIVES | MedImmune Limited (GB) | 2015-07-29 | — | — | EP | disclosed |
| EP-2898085-A1 | CELL LINES | MedImmune Limited (GB) | 2015-07-29 | — | — | EP | disclosed |
| CN-104812734-A | Amino acid derivatives | ALLOZYNE INC | 2015-07-29 | — | — | CN | disclosed |
| WO-2014044873-A1 | AMINO ACID DERIVATIVES | ALLOZYNE, INC (US) | 2014-03-27 | — | — | WO | disclosed |
| WO-2014044872-A1 | CELL LINES | ALLOZYNE, INC (US) | 2014-03-27 | — | — | WO | disclosed |
| WO-2014044872-A1 | CELL LINES | ALLOZYNE, INC (US) | 2014-03-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150259721-A1 | CELL LINES | AARS1, LARS1, IARS1 | OTC 2174/4885NOD1 4279/4885TDP1 863/4885 |
| US-10253345-B2 | Cell lines | AARS1, LARS1, IARS1 | OTC 2174/4885NOD1 4279/4885TDP1 863/4885 |
| US-20150251994-A1 | AMINO ACID DERIVATIVES | BCAT2, DNPEP, BCAT1 | OTC 2216/4885NOD1 4417/4885TDP1 4070/4885 |
| US-20170306381-A1 | CELL LINES | AARS1, LARS1, IARS1 | OTC 2174/4885NOD1 4279/4885TDP1 863/4885 |
| US-20170306380-A1 | AMINO ACID DERIVATIVES | BCAT2, DNPEP, BCAT1 | OTC 2216/4885NOD1 4417/4885TDP1 4070/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.